Danish pharmaceuticals manufacturer Lundbeck has appointed Barbara Jaszewski as vice president of global pricing and market access. The company says the move strengthens its capacity to bring drugs to market effectively prior to the launch of three new drugs in the coming 12 months.
Jaszewski takes charge of developing and strengthening a business area of growing strategic significance to Lundbeck as the company prepares to launch a range of drugs, including three during 2013: the antidepressant Brintellix (vortioxetine), Selincro (nalmefene) for the treatment of alcohol dependence, and aripiprazole once-monthly for the treatment of schizophrenia.
Collaborating with internal and external stakeholders at the firm’s Danish headquarters and affiliates worldwide, Jaszewski will lead the ongoing work of further building the company's global market access organisation.
Jaszewski has more than 20 years of experience in market access in the international pharmaceutical industry. She was previously director of global market access in the Berlin, Germany office of Bayer Healthcare, where she was responsible for setting up Bayer’s regional market access activities in Europe, Canada, Russia, Turkey, the Middle East and Africa. Prior to that, she held positions in the Canadian subsidiaries of Bayer and GlaxoSmithKline.